Establishment of the General Incorporated Association “Innovative Oncology Research Organization”
With the recent progress in global cancer research, cancer treatment is undergoing major changes. In particular, the development of cancer drugs and personalized treatment has made remarkable progress through molecular biology research and the introduction of AI. With the rapid progress in the development of new biopharmaceuticals, multiomics analysis data including spatial transcriptomics are becoming increasingly necessary for new basic drug discovery research. However, drug development and evidence creation in Japan, which are accepted globally, are limited, and a tendency of the long-term decline of top-level research capabilities and drug lag/loss have been highlighted.
To improve this situation, we have established the General Incorporated Association “Innovative Oncology Research Organization”. This organization will provide research grants after peer review for drug discovery, exploration research of biomarker targets, individualized treatment development research, etc. using new clinical, genomic/multiomics data obtained by basic and clinical researchers. We will support drug discovery and clinical development research in this area and promote the development of drugs and personalized treatment and the creation of global evidence from Japan.ion of global evidence from Japan.
We would appreciate your understanding and support in each relevant area for this organization to promote academic research that will contribute to new drug discovery and clinical development in Japan and will be accepted globally.
President of General Incorporated Association “Innovative Oncology Research Organization”
